The evidence library
Research on MV Health devices spans pelvic pain, arousal, lubrication and orgasm, erectile function, rehabilitation and ejaculation. Explore reported outcomes, patient experiences and clinical perspectives alongside the original publications.
Research on pelvic pain, arousal, lubrication, orgasm and experiences of care.
CrescendoDesign Uncontrolled pilot
21 recruited; 11 completed · 12 weeks
Investigators followed women with genito-pelvic pain/penetration disorder (GPPPD) during 12 weeks of home use of Crescendo.
CrescendoDesign Uncontrolled combined intervention
16 participants · 12 weeks
A multicenter study combined cognitive behavioral therapy (CBT), three educational sessions and Crescendo use in women with female sexual arousal disorder (FSAD).
Values shown are from the published abstract; the baseline and follow-up values differ from those in the company summary.
Crescendo 2Design Uncontrolled case series
19 participants · 6 and 12 weeks
A prospective case series evaluated Crescendo 2 use alongside education in women experiencing difficulty achieving orgasm during intercourse.
LegatoDesign Uncontrolled combined intervention
14 participants · 8 weeks
Investigators assessed Legato’s external focused mechanical vibration, alongside education, in women reporting arousal and lubrication difficulties.
MoltoDesign Case report
1 participant · 8 weeks
Investigators documented eight weeks of home use of Molto by one patient diagnosed with vaginismus and pain during penetration.
A fold increase cannot be calculated from a zero baseline. This result describes one patient.
Poco (company-attributed)Design Case report
1 participant · 6 weeks
A six-week case report followed a 46-year-old breast-cancer survivor with sexual interest/arousal disorder. MV Health identifies the study device as Poco.
PocoDesign Uncontrolled combined intervention
18 participants
Investigators studied sexual education combined with the Poco wearable device in 18 premenopausal women with female sexual interest/arousal disorder (FSIAD).
Poco (company-attributed)Design Qualitative study · company-reported
15 participants · 8 weeks (company summary)
A qualitative study explored scheduled device use in women with pelvic-floor disorders and sexual dysfunction; the company summary identifies Poco and a mean age of 60.3 years.
These are qualitative participant experiences, not measured comparative treatment effects.
Poco (company-attributed)Design Randomized controlled trial
84 randomized; 81 completed · 8 weeks
At a US referral center, women with pelvic-floor disorders and sexual dysfunction were randomized to an educational handout alone or the handout plus scheduled device use three times weekly.
Updated to the August 2026 journal report of the trial listed in the 2025 conference library. Poco attribution remains from MV Health; the accessible abstract does not name the model.
All DevicesDesign Mixed-methods study
19 interviews · median age 69 (range 23–75)
Investigators explored how urogynecology patients feel about discussing intimate-device use with their healthcare providers.
The supplied study report includes 19 interviews conducted from June 2024 to February 2025, analyzed using grounded theory methods. It concerns communication and patient experience, not treatment effectiveness.
PocoDesign Nonrandomized controlled pilot
30 enrolled; 19 analyzed (10 intervention, 9 control)
A feasibility and acceptability study followed women using Poco alongside standard vaginal dilator therapy and compared their experience with a non-device group.
Crescendo 2Design Study design unverified
Parameter-focused conference report
A conference poster examined Crescendo 2 stimulation parameters in women experiencing difficulties with orgasm, lubrication and arousal.
This may overlap with the situational-anorgasmia case series; it should not be counted as a separate independent trial without confirmation.
Research on erectile function, rehabilitation, chronic pelvic pain and ejaculation.
TenutoDesign Case report
1 participant · 5 weeks
Clinicians documented Tenuto use in a patient with neurogenic erectile dysfunction following colorectal-cancer surgery.
Tenuto 2Design Uncontrolled case series
7 participants · 8 weeks
Investigators evaluated eight weeks of on-demand Tenuto 2 use in seven men diagnosed with psychogenic erectile dysfunction.
The company summary cites an 81% score increase. Because the abstract’s instrument label and score range are inconsistent, that figure is not presented as a validated efficacy estimate.
Tenuto 2Design Case report
1 participant · 5 weeks in the poster text
The supplied IUGA 2024 poster describes Tenuto 2 use alongside daily tadalafil in a 74-year-old man with erectile dysfunction after prostate-cancer surgery and subsequent radiotherapy.
The supplied poster is available below as a B2B copy with the consumer-shop QR omitted; research content is unchanged. Its timeline graphic shows 15 and a 12-week label, which disagree with the written methods and results. The reported figures above follow the text; author clarification is needed.
Tenuto 2Design Uncontrolled combined intervention
16 participants · 6 months
Sixteen patients used Tenuto 2 alongside tadalafil and a penile pump after robotic-assisted radical prostatectomy, with erectile function assessed six months after surgery.
In the abstract, 11 is the lower end of the postoperative score range—not a pretreatment average. This is not an 11-to-19 improvement.
Tenuto MiniDesign Case report
1 participant · 2 months
Investigators evaluated Tenuto Mini in one man with situational, non-organic erectile dysfunction over two months of home use.
Tenuto MiniDesign Uncontrolled pilot
19 participants · 8 weeks
A preliminary study assessed Tenuto Mini use in men with psychogenic erectile dysfunction over an eight-week protocol.
Tenuto MiniDesign Uncontrolled observational study
30 men | 8 weeks
The complete correspondence reports an eight-week Tenuto Mini evaluation in men with psychogenic erectile dysfunction, using IIEF-5 and EDITS questionnaires.
Complete supplied article reviewed 2 November 2026. Keep this 30-person journal report separate from the earlier 19-person conference findings; participant overlap is not established.
MoltoDesign Exploratory case series
2 participants · 3 months
An early exploratory study evaluated Molto use in men with chronic non-bacterial prostatitis unresponsive to previous care.
MoltoDesign Uncontrolled preliminary study
20 recruited; 11 completed
Researchers assessed Molto as an insertable vibration aid in men experiencing delayed or absent ejaculation.
MoltoDesign Uncontrolled case series
13 participants · 8 weeks plus withdrawal follow-up
A prospective series followed 13 men using Molto during intercourse for eight weeks, with further assessment after device use stopped.
The withdrawal follow-up is important: the reported gains were not sustained after device use stopped.
MoltoDesign Case report
1 participant · 12 weeks
A 12-week case report evaluated Molto use in a 44-year-old man with refractory chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).
A multidisciplinary educational overview of sexual-health tools in clinical practice.
All DevicesFormat Educational discussion
Educational overview; no intervention cohort
Urologists, a urogynecologist, a pelvic physical therapist and a sex therapist discuss evidence and practical considerations for sexual-health devices.
Sources: MV Health’s clinical-validation register, supplied evidence documents and original publications. How this library was reviewed · Updated 13 September 2026. Where a summary differs from the accessible primary report, the primary report takes precedence. Company-reported findings are identified where full source verification remains outstanding.
Authors and affiliations are shown as credited in the publications, not as institutional endorsements of MV Health.
Back to search & filtersReading the research
These summaries describe research observations, not guaranteed outcomes or additional product indications. They are scientific and educational information for healthcare professionals.
The starting collection was MV Health’s clinical-validation register and the supplied clinical evidence documents. Each record identifies the relevant device or generation, research population, publication type and reported findings. Original journal reports, abstracts or posters are linked directly where available.
Accessible primary reports take precedence over company summaries. Company-reported results and verification gaps are marked rather than presented as independently confirmed. Combined treatments, small samples, overlapping reports and differences between product generations are called out; this is an appraised source collection, not a claim that every record is an independent clinical trial.
Download the clinical evidence review · Read the intended-use boundaries
FSFI is the Female Sexual Function Index. Higher domain scores generally indicate better function; a higher pain-domain score means less pain. IIEF / IIEF-5 measure erectile function; higher scores indicate better function. NIH-CPSI measures chronic prostatitis symptoms, and VAS is a pain rating scale; lower scores indicate fewer symptoms or less pain. EDITS measures satisfaction with erectile-dysfunction treatment.
Journal articles, conference abstracts, posters and individual cases provide different amounts of detail. Sample size, comparison groups, other treatments and follow-up all matter. A change in a questionnaire score is not a percentage of patients successfully treated. Reports may describe overlapping participants and should not be added together as independent trials.
Where a report records no device-related adverse events, this refers only to its participants and observation period. It does not establish safety for every patient. Some studies disclose industry funding, supplied devices or author consultancy; available disclosures are included with each record. Research findings do not replace the model-specific instructions for use or expand US product labelling.
